Capital Group Private Markets

Capital Group Private Markets, established in 1992, is a prominent player in emerging markets private equity, having invested over $5 billion in 80+ companies through its six private equity funds. The company adopts a global strategy to develop a diversified emerging markets portfolio. With a focus on Latin America, Capital Group Private Markets has been actively investing in Colombia for more than 15 years, showcasing its expertise and commitment to the region's growth and development.

Nick Chen

Partner

Leonard Kim

Managing Partner

3 past transactions

RealSelf

Series C in 2018
RealSelf, Inc. operates a platform that serves individuals considering elective cosmetic treatments. Founded in 2005 and based in Seattle, Washington, the company aims to enhance transparency in the cosmetic and aesthetic treatment market, which encompasses a diverse range of services from skin treatments to cosmetic surgeries. The platform allows users to access detailed information about various procedures, share personal experiences, and connect with medical providers. RealSelf features contributions from thousands of medical professionals who have answered over two million questions, provided educational videos, and shared patient testimonials, including before and after photos. This community-driven approach helps potential patients make informed decisions about their cosmetic treatment options.

Innovent Biologics

Series E in 2018
Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

D1 Stores

Secondary Market in 2016
At TIENDAS D1 we know that the key to differentiation is through the innovation of the articles in our stores and in this way we understand the needs of our customers, for this reason from the beginning of the conception of the products and until the last details are counted. with the perception and endorsement of the same consumer, information that is part of the strategic decisions for the permanent movements of the different categories, this is how we resort to sensory and performance tests of the products D1 Stores was established in 2009 in Medellín, Antioquia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.